trending Market Intelligence /marketintelligence/en/news-insights/trending/sXVYnvnRpaQSXngSVltm1g2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Myriad to seek FDA approval for companion test for AstraZeneca-Merck's Lynparza

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Myriad to seek FDA approval for companion test for AstraZeneca-Merck's Lynparza

Myriad Genetics Inc. plans to seek premarket approval from the U.S. Food and Drug Administration for its BRACAnalysis CDx as a companion diagnostic test for cancer drug Lynparza.

The company will file an application with the U.S. regulator to use the test to help identify prostate cancer patients with certain genetic mutations who are eligible for treatment with AstraZeneca PLC and Merck & Co. Inc.'s Lynparza, or olaparib.

BRACAnalysis CDx is already approved as a companion diagnostic test to identify patients with several cancer types, who are eligible to receive treatment with Lynparza.

AstraZeneca and Merck recently released results of a late-stage study, dubbed PROfound, which evaluated the efficacy and safety of Lynparza in treating patients whose castration-resistant prostate cancer had spread to other parts of the body and had the homologous recombination repair gene mutation, or HRRm.

Results showed that Lynparza helped patients with mutations in their BRCA1/2 or ATM genes live longer without radiographic progression, compared to Astellas Pharma Inc. and Pfizer Inc.'s Xtandi, and Johnson & Johnson's Zytiga.

The drug is already approved as maintenance therapy for certain ovarian cancer patients in the EU, U.S. and Japan. In the U.S., Lynparza is also approved to treat patients with BRCA-mutated breast cancer.

Salt Lake City-based Myriad and AstraZeneca have been collaborating for the diagnostic test related to Lynparza since 2007.